Below are the most recent publications written about "Receptor, ErbB-2" by people in Profiles.
-
Bhardwaj PV, Abdou Y. Navigating Treatment Pathways in Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies. J Clin Oncol. 2024 Dec; 42(34):4012-4017.
-
Gallo PM, Chain RW, Xu J, Whiteman LM, Palladino A, Caricchio R, Costa-Reis P, Sullivan KE, Gallucci S. EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon a-accelerated murine lupus. Int Immunopharmacol. 2024 Oct 25; 140:112692.
-
Ling AY, Jreich R, Montez-Rath ME, Meng Z, Kapphahn K, Chandross KJ, Desai M. Transporting observational study results to a target population of interest using inverse odds of participation weighting. PLoS One. 2022; 17(12):e0278842.
-
Murthy SRK, Cheng X, Zhuang T, Ly L, Jones O, Basadonna G, Keidar M, Canady J. BCL2A1 regulates Canady Helios Cold Plasma-induced cell death in triple-negative breast cancer. Sci Rep. 2022 03 08; 12(1):4038.
-
Ersoy E, Cao QJ, Otis CN. HER2 Protein Overexpression and Gene Amplification in Tubo-Ovarian High-grade Serous Carcinomas. Int J Gynecol Pathol. 2022 07 01; 41(4):313-319.
-
Liu B, Singh K, Gong S, Canakci M, Osborne BA, Thayumanavan S. Protein-Antibody Conjugates (PACs): A Plug-and-Play Strategy for Covalent Conjugation and Targeted Intracellular Delivery of Pristine Proteins. Angew Chem Int Ed Engl. 2021 06 01; 60(23):12813-12818.
-
Mollica V, Maggio I, Lopez-Beltran A, Montironi R, Cimadamore A, Cheng L, Rizzo A, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Massari F. Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. Expert Rev Anticancer Ther. 2020 09; 20(9):755-763.
-
Braman N, Prasanna P, Whitney J, Singh S, Beig N, Etesami M, Bates DDB, Gallagher K, Bloch BN, Vulchi M, Turk P, Bera K, Abraham J, Sikov WM, Somlo G, Harris LN, Gilmore H, Plecha D, Varadan V, Madabhushi A. Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer. JAMA Netw Open. 2019 04 05; 2(4):e192561.
-
Amornsiripanitch N, Nguyen VT, Rahbar H, Hippe DS, Gadi VK, Rendi MH, Partridge SC. Diffusion-weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER+/HER2- breast cancers. J Magn Reson Imaging. 2018 07; 48(1):226-236.
-
Birkness JE, Spada NG, Miller C, Luketich JD, Nason KS, Sun W, Davison JM. Extreme chromosome 17 copy number instability is a prognostic factor in patients with gastroesophageal adenocarcinoma: A retrospective cohort study. Genes Chromosomes Cancer. 2018 01; 57(1):28-34.